



COVID-19 Provider Update

Wednesday, October 20, 2021



Population Coverage: As of October 19

Age range	% of Population	CT Population	At least one dose		Fully vaccinated		Third doses		Total Doses Administered
			Number	%	Number	%	Number	%	
12+	87%	3,105,947	2,580,195	83.1%	2,387,510	76.9%	145,543	4.7%	4,936,468
16+	82%	2,929,347	2,456,765	83.9%	2,279,137	77.8%	145,478	5.0%	4,704,610
18+	80%	2,837,847	2,383,997	84.0%	2,212,534	78.0%	145,418	5.1%	4,565,228
35+	57%	2,047,745	1,807,289	88.3%	1,696,971	82.9%	140,906	6.9%	3,521,545
45+	45%	1,620,604	1,455,281	89.8%	1,373,627	84.8%	135,481	8.4%	2,875,762
55+	32%	1,143,699	1,062,788	92.9%	1,004,855	87.9%	127,507	11.1%	2,136,625
65+	18%	630,244	597,663	94.8%	562,213	89.2%	110,905	17.6%	1,252,898
75+	8%	277,425	255,761	92.2%	239,664	86.4%	54,376	19.6%	543,704

Data as reported to CT DPH Immunization Information System (IIS) CT WiZ.
 All ages estimate includes 172 people with unknown age



Age coverage: Specific age groups

Doses Reported by 10/19/2021

Age Range	% of Population	CT Population	At least one dose		Fully vaccinated		Third doses		Total Doses Administered
			Number	%	Number	%	Number	%	
12-15	5%	176,600	123,430	69.9%	108,373	61.4%	65	0.0%	231,858
16-17	3%	91,500	72,768	79.5%	66,603	72.8%	60	0.1%	139,382
18-24	10%	342,073	239,587	70.0%	212,271	62.1%	820	0.2%	431,563
25-34	13%	448,029	337,121	75.2%	303,292	67.7%	3,692	0.8%	612,120
35-44	12%	427,141	352,008	82.4%	323,344	75.7%	5,425	1.3%	645,783
45-54	13%	476,905	392,493	82.3%	368,772	77.3%	7,974	1.7%	739,137
55-64	14%	513,455	465,125	90.6%	442,642	86.2%	16,602	3.2%	883,727
65-74	10%	352,819	341,902	96.9%	322,549	91.4%	56,529	16.0%	709,194
75-84	5%	186,095	180,633	97.1%	169,241	90.9%	41,170	22.1%	387,132
85+	3%	91,330	75,128	82.3%	70,423	77.1%	13,206	14.5%	156,572
Grand Total		3,565,287	2,580,367	72.4%	2,387,601	67.0%	145,543	4.1%	4,936,719

*At least one dose includes individuals who have received one dose of Pfizer, Moderna, or J&J

**Fully vaccinated includes individuals who received one dose of J&J, two doses of Moderna, or two doses of Pfizer.

Total excludes 172 people with unknown age



Booster Updates

Moderna Booster

VRBPAC voted unanimously to recommend authorization of a booster dose of Moderna's COVID vaccine at least 6 months after completion of the primary series for those 65+ years and others 18-64 years who are at high risk for seriously illness from COVID-19 or being high risk of occupational or setting exposure (*same recommendation as for Pfizer booster*)

J&J Booster

VRBPAC voted unanimously to recommend authorization of a booster dose of the J&J vaccine for everyone 18 and older who got the primary dose of J&J COVID vaccine at least 2 months ago

“Mix & Match”

VRBPAC did not vote this week on whether to recommend a “mix & match” approach to booster doses (heterologous boosters). The idea of getting a booster from a different vaccine than the one originally taken was discussed, with experts reviewing new data from a National Institutes of Health (NIH) study

We are awaiting final recommendations from FDA

ACIP is meeting today and tomorrow (Oct 20 & 21): meeting is streamed online [here](#)

Vaccinating the *unvaccinated* is still a top priority.



Reminder: Moderna booster

The Moderna booster is a half dose

Shipments of the Moderna vaccine shipped after the EUA is extended to boosters will have syringes and kits to draw 20 doses from a vial

Providers should not draw more than 20 doses from an individual vial (e.g., a 14-dose vial should not be used to draw 28 boosters – stop at 20 and discard the rest)



Pfizer Age Expansion to 5-11

FDA VRBPAC meeting scheduled for 10/26/21 and can be viewed [here](#).

ACIP meeting scheduled for 11/2-11/3. Agenda is not yet available; information can be found [here](#).

The Pfizer Vaccine for 5–11-year-olds will be a new product with new packaging and a new national drug code (NDC).

Current product for adults and adolescents should not be used in children under 12.



Orders are open now!

Place an order for the Pfizer 5-11 COVID-19 vaccine for week 1 of distribution (week of November 1), using this [order form](#)

Priority will be given to orders placed by tomorrow (Thursday, Oct 21) morning

Pfizer-BioNTech COVID-19 Vaccines

PRELIMINARY – SUBJECT TO CHANGE PENDING REGULATORY GUIDANCE AND AUTHORIZATION/APPROVAL

Description	Current Adult/Adolescent Formulation (1170 and 450 packs)	Future Pediatric Formulation
	Dilute Prior to Use	Dilute Prior to Use
Age Group	12 years and older	5 to <12 years**
Vial Cap Color	PURPLE 	ORANGE 
Dose	30 mcg	10 mcg
Injection Volume	0.3 mL	0.2 mL
Fill Volume (before dilution)	0.45 mL	1.3 mL
Amount of Diluent* Needed per Vial	1.8 mL	1.3 mL
Doses per Vial	6 doses per vial (after dilution)	10 doses per vial (after dilution)
Storage Conditions		
ULT Freezer (-90°C to -60°C)	9 months	6 months
Freezer (-25°C to -15°C)	2 weeks	N/A
Refrigerator (2°C to 8°C)	1 month	10 weeks

Q: Can the current adult/adolescent formulation (purple cap) be used to vaccinate children 5 to <12 years old once the vaccine is authorized for this age group?

A: No. For children under 12 years of age, you cannot use the current formulation and will need to use the future pediatric (orange cap) formulation.

Purple Cap – Adult/Adolescent: Authorized only for aged 12 years and older



Orange Cap – Pediatric: Future authorization for aged 5- to 12 years. A separate vaccine formulation specific for a 10mcg dose will be introduced.



NOTE: Use of the current adult/adolescent formulation (purple cap) to prepare doses for children 5 to <12 years would result in an injection volume for the 10mcg dose of 0.1mL, which is both generally considered too small for typical IM injections and has not been studied.

*Diluent: 0.9% sterile Sodium Chloride Injection, USP (non-bacteriostatic; DO NOT USE OTHER DILUENTS

**The vaccine is currently under emergency use authorization review by the Food and Drug Administration (FDA) for children 5 to <12 years old



Pfizer 5-11 Product: Ordering information

Reminder: Current product for adults and adolescents should not be used in children under 12

Ordering is now open for deliveries for the first week of 5-11 product introduction

We expect these deliveries to arrive early the week of November 1st

Deliveries that arrive before ACIP should wait until ACIP concludes prior to administration

More information about Week 2 orders will be made available soon – we are awaiting guidance from the CDC

Orders are open now!

Place an order for the Pfizer 5-11 COVID-19 vaccine for week 1 of distribution (week of November 1), using [this order form](#)

Priority will be given to orders placed by tomorrow (Thursday, Oct 21) morning



Pfizer 5-11 Product: Connecticut numbers and allocation

For the new Pfizer 5-11 product, there is limited quantity available, but it should be plenty to satisfy initial demand across the State

Connecticut has been given a “Week 1 allocation” of ~96,000 doses; Pharmacies in Connecticut will receive an additional direct allocation of ~48,000 doses – this is a total of roughly ~144,000 doses

FQHCs need to place their order through Connecticut DPH (not HRSA)

There are approximately 280,000 kids 5-11 in Connecticut, so this initial Week 1 distribution is sufficient to offer vaccine to more than 50% - *we do not anticipate meaningful or lasting supply constraints*



Reminders

There will be some new providers for the 5-11 age group (e.g., pediatric groups that did not previously provide COVID vaccines)

As a reminder:

- Make sure you schedule second doses at the time of the first dose; conduct active reminder recall
- All dose administration must be reported electronically within 24 hours
- Ensure patient record and information is complete – including race & ethnicity information
- Help get people caught up on other vaccines – and offer flu!*




Updated CDC Guidance for fully Vaccinated Persons

CDC recently made changes to the following guidance for fully vaccinated persons.

[When You've Been Fully Vaccinated | CDC](#) and [Interim Public Health Recommendations for Fully Vaccinated People | CDC](#)

Vaccine providers should review the newly added [Annex](#), which describes what vaccines qualify people as fully vaccinated and how to interpret vaccine records. This annex includes guidance on how to assess heterologous (i.e., mix-and-match) primary series and records that include non-FDA approved or authorized vaccine.

Additional COVID-19 Vaccine guidance can be found at [Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States | CDC](#).



Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12–18 Years — United States, June–September 2021



CT WiZ/VAMS Update



CT WiZ News

Version 0.1
10/20/2021



Default Provider/Clinic

Provider/Clinic : CT DPH CLINIC, CT DPH CLINIC

SELECT A CLINIC BY TYPING PROVIDER, CLINIC, VFC PIN, OR CLINIC CODE



News

[10/14/2021] - **Special Procedure for Wasted/Expired COVID-19**

Providers should dispose of expired vaccine appropriately and report wastage in the [Helpdesk](#), select "Report Vaccine Wastage" - "Other" as the wastage reason and type "Expiration" in the text box. **Update inventory** in: Vaccine Finder, VAMS, or CT WIZ as appropriate.

Best practices: regularly check inventory for expired vaccine and remove expired inventory to prevent it from being administered. If you have not yet registered for the report, visit [CDC's Vaccine Lot Number and Expiration Date webpage](#) and complete the registration form to request access. [Moderna](#) and [J&J](#) also have expiration date look up websites

[07/10/2019] - **"Add and Administer"** (initial step required)

New patients created by Vital Records are displaying a blue link in the immunizations page with the message **"Please enter required information on Patient Demographics screen prior to entering immunizations"** that **must be cleared before** you are able to: add and administer vaccines from inventory, and enter vaccine refusals (**please see attached instructions.**)

Attachments:

[Click here to see instructions](#)



Question and Answers

To ask a question, please raise your hand using the hand icon on your screen, type your question in the chat box or if you are on the phone press *6 to unmute yourself.

If you have additional questions after the meeting, please feel free to email them to DPH.Immunizations@ct.gov

You can fill out a help desk ticket by visiting <https://dph-cthelpdesk.ct.gov/Ticket>